Aim The present study aimed to determine the real‐world efficacy and safety of the non‐
structural protein (NS) 5A inhibitor elbasvir (EBR) combined with the NS3/4A protease …

Summary Elbasvir (EBR; HCV NS 5A inhibitor) and grazoprevir (GZR; HCV NS 3/4A
protease inhibitor) are approved as a fixed‐dose combination to treat patients chronically …

Background A 12-week grazoprevir/elbasvir regimen is highly effective against hepatitis C
virus genotype 1 (HCV-1) infection. The efficacy of an 8-week regimen for treatment-naive …

Background The real-world virological efficacy and safety of an interferon (IFN)-free direct-
acting antiviral (DAA) therapy with elbasvir (EBR) and grazoprevir (GZR) were evaluated in …

Purpose Hepatitis C virus (HCV) infection is a major healthcare concern in Russia, where
almost 5 million individuals are viremic. Elbasvir/grazoprevir is a fixed-dose combination …

The prevalence of hepatitis C virus (HCV) infection in Asian countries is high. This study
assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) in participants with HCV …

Hepatitis C virus (HCV) genotype (gt) 3 is highly prevalent globally, with non‐gt3a subtypes
common in Southeast Asia. Resistance‐associated substitutions (RASs) have been shown …

In randomized controlled trials of patients with chronic HCV infection, elbasvir/grazoprevir
(EBR/GZR) demonstrated high cure rates and a good safety profile. This study assessed the …

Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite
worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low …

Objectives Genetic variability in NS5A is associated with different levels of resistance to the
currently licensed NS5A inhibitors. The aim of this study was to detect NS5A inhibitor …